What is CMR Versius?

CMR Versius: international commercial soft-tissue surgical archetype

CMR Versius is a modular soft-tissue surgical robotic system from CMR Surgical, a UK-based company founded in 2014. Per DEPLOY's surgical cluster framework, Versius anchors the international commercial soft-tissue surgical archetype within the surgical cluster, extending the cluster's structural axes from FDA-clearance-posture (Wave 1) into clinical-domain + commercial-model variance.

---

CMR Surgical: UK-based, founded 2014

CMR Surgical is a UK-based surgical robotics company founded in 2014, headquartered in Cambridge. The CMR + Versius lineage represents the UK + European surgical robotics industrial base extending into the broader surgical cohort: distinct from US-headquartered cluster anchors (Intuitive Surgical + J&J Ottava) and from international cohort entries at distinct geographic-industrial-base layers.

---

Modular architecture (distinct from Intuitive monolithic design)

Per DEPLOY's surgical cluster framework, Versius operates a modular architecture structurally distinct from Intuitive da Vinci's monolithic design:

• Versius (modular): separate cart-mounted instrument arms; each arm operates as an independent mobile unit; surgeons select 2-4 arms per procedure based on case requirements.
• Intuitive da Vinci (monolithic): single patient-side cart with 3-4 arms in fixed configuration; the entire patient-side cart positioned as one unit at the operating table.

The modular-vs-monolithic architectural distinction is editorially significant at the cohort-architecture layer: trade-press coverage that frames Versius as "another teleoperated soft-tissue system competing with da Vinci" operates at insufficient architectural-distinction scope. Per DEPLOY's framework, the modular design enables distinct OR-footprint patterns + case-by-case arm-count configuration that differ structurally from monolithic deployment.

---

Commercial deployment: EU + UK + Australia + India (cap-flag specific figures)

Per DEPLOY's surgical cluster framework, Versius operates established commercial deployment volume across:

• European Union: multi-country commercial deployment.
• United Kingdom: home-market established commercial position.
• Australia: commercial deployment.
• India: commercial deployment.

Per cap-flag-as-trust-signal, specific deployment figures cap-flagged pending primary-source confirmation: aggregator-quoted deployment counts vs CMR-disclosed deployment counts may vary; CMR-disclosed primary-source confirmation is load-bearing. The international-commercial deployment framing is the load-bearing verified scope; specific deployment-count figures operate at lower verification posture pending primary-source confirmation.

---

US FDA clearance state: cap-flag pending primary-source confirmation

Per DEPLOY's surgical cluster framework, US FDA clearance state operates at cap-flag posture pending primary-source confirmation of current submission status (pending vs received vs Q4 2024 510(k) submission status varies across aggregator coverage). Per cap-flag-as-trust-signal, the US-market state framing requires precise primary-source verification at any specific verification claim.

Per DEPLOY's framework, the non-US-market commercial deployment (established across EU + UK + Australia + India) is the load-bearing verified-commercial-deployment framing; the US market access state operates at honest-absence pending current primary-source confirmation.

---

Cohort positioning: international commercial soft-tissue surgical archetype

Per the surgical cluster framework, CMR Versius anchors:

• International commercial soft-tissue surgical archetype: commercial deployment across EU + UK + Australia + India; UK-headquartered industrial base.
• Modular architecture distinction: separate cart-mounted instrument arms; distinct from Intuitive monolithic patient-side cart.
• US FDA clearance state at honest-absence posture: current submission status cap-flagged.
• Three structural editorial axes within one entity: international commercial + modular-architecture + non-US-market state.

Contrast with cohort:

• Intuitive da Vinci: market-leader installed-base anchor; 11,395 da Vinci systems + 1,041 Ion systems per SEC 10-Q; monolithic architecture.
• J&J Ottava: pre-market research tier; De Novo submission January 2026; FDA records "not authorized to be marketed."
• Moon Surgical Maestro: assistive-laparoscopy archetype; FDA 510(k) K240598 cleared Jun 2024; assistive-vs-replacement positioning.

The Wave 2 expansion's structural point: Wave 1 surgical FDA-clearance triangle covered general-laparoscopy variance across FDA-clearance states; Wave 2 extends into clinical-domain + commercial-model variance. Three structural axes now live on surgical cluster: FDA-clearance-posture (Wave 1) + clinical-domain (Wave 2) + commercial-model (Wave 2).

Consumer pricing surface for CMR Versius is forthcoming via Agent B's parallel surgical /price expansion; per cap-flag-as-trust-signal, the consumer-price-page is documented as forthcoming honest-absence pending Agent B's parallel ship. Registry institutional depth at CMR Surgical registry company + Versius registry model.

For the canonical surgical cluster context, see the surgical robotics cluster. For the market-leader installed-base context, see what is Intuitive Surgical da Vinci. For the canonical category umbrella, see what is physical AI. For methodology canonical references applicable to CMR Versius: the 4-way autonomy-boundary taxonomy (replacement-robotics teleoperated tier; international commercial soft-tissue) + the 9-tier source-quality rubric (CMR IR + reputable-press + US FDA clearance state source classification).